Search research articles
Contact Us
Filters
Showing results (501-510 of 534) with videos related to
Page
of 54
Sort By:
Nature Immunology
|
July 20, 2021
Distinct transcription factor networks control neutrophil-driven inflammation
Tariq E Khoyratty, Zhichao Ai, Ivan Ballesteros, et al.
Cell Discovery
|
December 10, 2020
Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro
Qi Zhang, Catherine Zhengzheng Chen, Manju Swaroop, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 30, 2025
Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer
Sihong Chen, Mengyan Zhong, Xiaoyuan Wang, et al.
Biorxiv : the Preprint Server for Biology
|
July 24, 2020
Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs <i>in vitro</i>
Qi Zhang, Catherine Z Chen, Manju Swaroop, et al.
Blood
|
September 22, 2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors
Mustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, et al.
Blood
|
December 11, 2012
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
Athina Giannoudis, Lihui Wang, Andrea L Jorgensen, et al.
Scientific Reports
|
February 16, 2017
Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer
Jie Zhang, Shumei Feng, Wenmei Su, et al.
Science Advances
|
October 5, 2022
Plasma iron controls neutrophil production and function
Joe N Frost, Sarah K Wideman, Alexandra E Preston, et al.
Oncotarget
|
April 1, 2015
Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness
Wei Ma, Gary Guishan Xiao, Jun Mao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2011
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
David Marin, Amr R Ibrahim, Claire Lucas, et al.
Page
of 54
Search research articles
Search
Showing results (501-510 of 534) with videos related to
Sort By:
Page
of 54
Nature Immunology
|
July 20, 2021
Distinct transcription factor networks control neutrophil-driven inflammation
Tariq E Khoyratty, Zhichao Ai, Ivan Ballesteros, et al.
Cell Discovery
|
December 10, 2020
Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro
Qi Zhang, Catherine Zhengzheng Chen, Manju Swaroop, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 30, 2025
Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer
Sihong Chen, Mengyan Zhong, Xiaoyuan Wang, et al.
Biorxiv : the Preprint Server for Biology
|
July 24, 2020
Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs <i>in vitro</i>
Qi Zhang, Catherine Z Chen, Manju Swaroop, et al.
Blood
|
September 22, 2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors
Mustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, et al.
Blood
|
December 11, 2012
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
Athina Giannoudis, Lihui Wang, Andrea L Jorgensen, et al.
Scientific Reports
|
February 16, 2017
Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer
Jie Zhang, Shumei Feng, Wenmei Su, et al.
Science Advances
|
October 5, 2022
Plasma iron controls neutrophil production and function
Joe N Frost, Sarah K Wideman, Alexandra E Preston, et al.
Oncotarget
|
April 1, 2015
Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness
Wei Ma, Gary Guishan Xiao, Jun Mao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2011
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
David Marin, Amr R Ibrahim, Claire Lucas, et al.
Page
of 54